Methsuximide

CHEMBL697 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

203.2 g/mol

LogP

1.2

Phase

4

An anticonvulsant medication used to control absence seizures (brief lapses of consciousness) in patients with epilepsy who have not responded to other seizure medications. It works by reducing abnormal electrical activity in the brain.

Molekularmasse

203,2400 g/mol

LogP

1,20

TPSA

37,40 Å²

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Epilepsy

Wirkmechanismus

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1C(=O)CC(C)(c2ccccc2)C1=O

InChI

InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3

Molecular Formula

C12H13NO2

HBD / HBA

- / 2

Rotierbare Bindungen

1

Schwere Atome

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

An anticonvulsant medication used to control absence seizures (brief lapses of consciousness) in patients with epilepsy who have not responded to other seizure medications. It works by reducing abnormal electrical activity in the brain.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Methsuximide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL697. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6476. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Methsuximide auf PillFYI

Struktur

Schnelldaten

Formel: C12H13NO2
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.